BCT Share Price Performance
Recent BCT News & Updates
No updates
BriaCell Therapeutics Corp. Key Details
Last Reported Earnings
Apr 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -2.87
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
BriaCell Therapeutics Corp. Competitors
About BCT
- Founded
- n/a
- Employees
- 16
- CEO
- WebsiteView website
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Canadian Market Performance
- 7 Days: 0.02%
- 3 Months: 11.9%
- 1 Year: 16.6%
- Year to Date: 9.6%
The market has been flat over the last week. As for the longer term, the market has risen 17% in the past 12 months. Looking forward, earnings are forecast to grow by 12% annually. Market details ›
The tide is turning for UK & European markets. Index ETFs won’t cut it since sector spreads are massive. Picking the right companies matters now more than ever.
Continue readingLast Week
